Почетна › ХОБП › Јужна Каролина
Kliničke studije za ХОБП u državi Јужна Каролина
17 studija za ХОБП traži učesnike na lokacijama u državi Јужна Каролина.
Gradovi u državi Јужна Каролина
Zvanični tekst studije (na engleskom)
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
- Copd01 50020, North Charleston
- Copd01 50004, Rock Hill
- Copd01 50009, Spartanburg
- и још 1
Тражи се учесникФаза 2
Узраст од 40 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07725939Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
- Lowcountry Lung & Critical Care, PA ( Site 4413), Charleston
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07874815A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
- PanAmerican Clinical Research, Bluffton
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07908381To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Clinical Research of Rock Hill, Rock Hill
Тражи се учесникФаза 2
Узраст од 40 до 85 · Оба пола · Ажурирано 28. 10. 2026. · NCT07684820A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 101, Charleston
Тражи се учесникФаза 3
Узраст од 18 до 80 · Оба пола · Ажурирано 26. 10. 2026. · NCT07555483A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Lancaster
- Research Site, Spartanburg
Тражи се учесникФаза 2
Узраст 40 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- MedTrial- Site Number : 8400010, Columbia
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 23. 10. 2026. · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Bogan Sleep Consultants, LLC, Columbia
- Velocity Clinical Research, Gaffney, Gaffney
- Clinical Research of Rock Hill, Rock Hill
- и још 1
Тражи се учесникФаза 2/3
Узраст од 35 до 80 · Оба пола · Ажурирано 22. 10. 2026. · NCT07363694Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- AnMed Oglesby Center- Site Number : 8400074, Anderson
- MD First Research - Lancaster- Site Number : 8400102, Lancaster
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 19. 10. 2026. · NCT07190209STRIVE Post-Market Registry Study
- AnMed Health, Anderson
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT04302272A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Anderson
- Research Site, Columbia
- Research Site, Gaffney
- и још 2
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 9. 10. 2026. · NCT06878261Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Union
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 5. 10. 2026. · NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 5. 10. 2026. · NCT06959095A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Anderson
- Research Site, Charleston
- Research Site, Gaffney
- и још 2
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 2. 10. 2026. · NCT06283966A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Rock Hill
Тражи се учесникФаза 3
Узраст од 40 до 80 · Оба пола · Ажурирано 3. 9. 2026. · NCT06883305eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
Тражи се учесникФаза 3
Узраст од 40 до 75 · Оба пола · Ажурирано 28. 7. 2026. · NCT07177339Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Medical University of South Carolina (MUSC), Charleston
- McLeod Health, Florence
Тражи се учесникОпсервациона студија
Узраст 50 и старији · Оба пола · Ажурирано 5. 8. 2025. · NCT06122077Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.